Press Room

11 Nov 2008 Trends in the diabetes drug pipeline 2008
28 Oct 2008 The future of human insulin: tailored and oral
07 Oct 2008 Human growth hormone (hGH): biosimilar pricing is not enough, convenience will mandate
10 Sep 2008 Takeda reigns supreme among Japanese pharma companies
28 Aug 2008 Emerging diabetes drugs consider beta cell mass and function as an important target
12 Aug 2008 The third generation of TPO mimetics are again biologics
07 Aug 2008 The changing marketplace of antithrombotics: better than cheaper?
23 Jul 2008 Erythropoietins: the shift from biosimilars to “more for less” ESAs
28 Mar 2008 Cancer and TNF antibodies boost Biologics Sales in 2007
11 Feb 2008 2008 is a decisive year for the validation of the asthma target interleukin-13
23 Jul 2007 114 Blockbuster Drugs Accounted for 2006 Sales of US$ 233.7 bln
30 May 2007 The imminent change of the antithrombotics market
02 May 2007 Up and down with cholesterol management
25 Apr 2007 Beyond biogenerics: the real threats for therapeutic proteins
15 Mar 2007 La Merie and PharmaPlus team up to provide No-Frills business intelligence solutions
08 Mar 2007 Weight management is not enough for cannabinoid type 1 (CB1) receptor antagonists to become a commercial success
01 Mar 2007 The new class of dipeptidyl peptidase IV (DPP-IV) inhibitors has one clear leader and many followers
26 Feb 2007 TOP Classes of Biologics with 2006 Sales of US$ 63.8 bln
14 Feb 2007 The market of recombinant coagulation factors is growing with next generation products
05 Feb 2007 Dosing convenience is mandatory to keep pace in the pipeline race of GLP-1 analogs for type 2 diabetes
02 Feb 2007 Overview On 2006 Sales Of TOP 20 Biologics To Be Released On February 26
11 Jan 2007 The right balance drives the field of PPAR agonist R&D

La Merie Biologics

FREE Weekly News Bulletin

2016 Sales ofAntibodies & Proteins

New Product Alert

For La Merie Publishing

Top